MEA HIV Therapeutics Market

The size of the Middle East & Africa HIV Therapeutics Market was worth USD 1.84 billion in 2024 and estimated to be growing at a CAGR of 1.58%, to reach USD 1.99 billion by 2029. The human immunodeficiency virus (HIV) refers to a kind of retrovirus that causes (AIDS).

HIV affects some immune cells and it weakens the immune system bringing about loss of capacity to fight against the organisms that cause diseases. HIV spreads through the exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV infected. Additionally, HIV can spread from infected mother to child during pregnancy. Here are some of the symptoms of HIV disease are weakness, slight fever, swollen glands, cerebral pains and muscle hurts. HIV infection has no cure however there are medicines that help to balance out or decrease this infection so it doesn't prompt AIDS. HIV therapeutics market is developing at a significant rate because of increment in the HIV infected cases and developing awareness about the same.

An increasing number of HIV affected cases, an innovative advancement in HIV diagnosis and therapeutics, ascend in research exercises for developing HIV immunizations and not aware of the methods of transmission of the infection are driving the worldwide market for HIV therapeutics. Moreover, increasing awareness about the accessibility of HIV therapeutics in the market and cost-effective sedate treatments for HIV are driving the Middle East and Africa HIV Therapeutics Market.

Be that as it may, different variables, for example, the disappointment of treatment sometimes, absence of gifted experts and presentation of non-specific medications in the market are major restraints in the Middle East and Africa HIV Therapeutics Market.

This research report on the Middle East & Africa HIV Therapeutics Market has been segmented and sub-segmented the market into the following categories

By Type

• Nucleoside/Tide Reverse Transcriptase Inhibitors
• Nucleoside/Tide Analogues
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Integrase Inhibitors
• CCR5 Inhibitors
• Fusion Inhibitors

By Application

• HIV Type-1
• HIV Type-2

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Leading companies operating in the MEA HIV Therapeutics Market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche and Gilead Sciences.